Genome-wide investigation of an ID cohort reveals de novo 3 ' UTR variants affecting gene expression by Devanna, P. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Vol.:(0123456789) 
Human Genetics (2018) 137:717–721 
https://doi.org/10.1007/s00439-018-1925-9
ORIGINAL INVESTIGATION
Genome-wide investigation of an ID cohort reveals de novo 3′UTR 
variants affecting gene expression
Paolo Devanna1 · Maartje van de Vorst2 · Rolph Pfundt2 · Christian Gilissen2 · Sonja C. Vernes1,3 
Received: 26 June 2018 / Accepted: 6 August 2018 / Published online: 10 August 2018 
© The Author(s) 2018
Abstract
Intellectual disability (ID) is a severe neurodevelopmental disorder with genetically heterogeneous causes. Large-scale 
sequencing has led to the identification of many gene-disrupting mutations; however, a substantial proportion of cases lack 
a molecular diagnosis. As such, there remains much to uncover for a complete understanding of the genetic underpinnings 
of ID. Genetic variants present in non-coding regions of the genome have been highlighted as potential contributors to neu-
rodevelopmental disorders given their role in regulating gene expression. Nevertheless the functional characterization of 
non-coding variants remains challenging. We describe the identification and characterization of de novo non-coding varia-
tion in 3′UTR regulatory regions within an ID cohort of 50 patients. This cohort was previously screened for structural and 
coding pathogenic variants via CNV, whole exome and whole genome analysis. We identified 44 high-confidence single 
nucleotide non-coding variants within the 3′UTR regions of these 50 genomes. Four of these variants were located within 
predicted miRNA binding sites and were thus hypothesised to have regulatory consequences. Functional testing showed 
that two of the variants interfered with miRNA-mediated regulation of their target genes, AMD1 and FAIM. Both these vari-
ants were found in the same individual and their functional consequences may point to a potential role for such variants in 
intellectual disability.
Introduction
Intellectual disability is a genetically heterogeneous disor-
der, and severe cases occur in about 0.5% of all children 
(Ropers 2010). Previous studies of ID cohorts have focused 
on large copy number variants (CNVs), or single nucleotide 
variants (SNVs) located in protein coding regions, to dis-
cover genetic factors contributing to ID. These studies have 
used a range of techniques including CNV arrays, whole 
exome sequencing (WES), and whole genome sequenc-
ing (WGS), and have dramatically increased the number of 
genes that contribute to this disorder. However, 38–73% of 
ID cases remain unexplained (Bowling et al. 2017; Gilissen 
et al. 2014; Monroe et al. 2016; Rauch et al. 2012; Hamdan 
et al. 2014).
Variants that affect non-coding regulatory regions of the 
genome may influence brain development and function via 
their critical role in regulating gene expression, and have 
been previously implicated in neurodevelopmental disorders 
(Wanke et al. 2018). In this study, we hypothesised that de 
novo variation in 3′UTR regulatory regions may be a pos-
sible mechanism through which non-coding mutations con-
tribute to ID. We interrogated WGS data from a previously 
described cohort of 50 individuals (Gilissen et al. 2014) 
diagnosed with severe ID (IQ < 50), and their unaffected 
parents, to identify de novo 3′UTR mutations and investigate 
their functional consequences.
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Subjects and methods
All 50 patients had a diagnosis of severe intellectual dis-
ability (IQ < 50) and had previously been screened via diag-
nostic genomic CNV arrays, WES and WGS (Gilissen et al. 
2014). Within the group of patients that underwent all the 
diagnostic stages, 21 patients (42%) received a molecular 
diagnosis as a result of this screening. 20 patients carried 
coding variants that were not considered pathogenic; the 
remaining 9 patients did not carry any de novo coding vari-
ants [(Gilissen et al. 2014) and see also Fig. 1]. We inter-
rogated the WGS data for this cohort to identify de novo 
variants that were located within predicted miRNA binding 
sites in 3′UTR regions. This was performed by overlapping 
the position of all the de novo variants with the coordinates 
for miRNA binding sites identified by Targetscan 7.0 (Lewis 
et al. 2005) using BEDTools (Quinlan and Hall 2010), as 
described previously (Devanna et al. 2018).
Construct cloning and reporter assays were performed 
as described previously (Devanna et al. 2018). Briefly, 
miRNA expression constructs were cloned into pLKO.1 
expression vector (Invitrogen) and 3′UTR reporter con-
structs carrying the reference (+) or variant (Var) sequence 
were cloned into the pmiR-GLO luciferase expression 
vector (Promega), using the oligonucleotides described in 
Table S1. All inserts were confirmed by Sanger sequenc-
ing. For functional assays, reporter constructs were co-
transfected into HEK293 cells alongside the relevant 
miRNA expression vector. 48 h post-transfection, firefly 
luciferase and renilla luciferase activities were meas-
ured as per manufacturer’s instructions (Dual Luciferase 
reporter assay system, Promega). MiRNA sensors (i.e., 
luciferase reporters designed to be maximally responsive 
to the cognate miRNA) were included as positive controls 
to confirm that the overexpressed miRNA was active (see 
Fig. S1).
Statistical significance was calculated for the refer-
ence alleles (Fig. 2a) using a pairwise t test, and for the 
variants (Fig. 2b) via ANOVA followed by post hoc Tukey 
calculation. All experiments were repeated three times, 
and within each experiment there were three independent 
transfections measured for each condition.
Fig. 1  Non-coding variants were identified in a cohort of 50 patients 
with severe ID. a In the cohort of 50 patients, 4081 total, high-con-
fidence de novo variants were identified to be genome wide [refer 
to Gilissen et  al. (2014 ) for the discovery of these variants]. From 
these, 80 were exonic and 193 were found in UTR regions (5′UTR 
and 3′UTR). 44 variants were identified in 3′UTRs, of which 4 were 
predicted to disrupt putative miRNA binding sites. b Of the 50 ID 
patients that were previously sequenced using WGS, 42% of patients 
received a molecular diagnosis—i.e., de novo coding changes were 
identified that were thought to be causative. 58% of patients did not 
carry pathogenic de novo coding mutations; 40% of these  had non-
pathogenic de novo coding variants, and 18% did not have any de 
novo changes in coding (exonic) regions (Gilissen et al. 2014). c The 
four de novo variants predicted to disrupt miRNA binding sites were 
identified in three different patients. Previous studies had not identi-
fied any de novo coding mutations in these patients that were likely to 
explain the phenotype
719Human Genetics (2018) 137:717–721 
1 3
Results
From WGS data of 50 severely affected ID patients, we iden-
tified all de novo SNVs located within 3′UTR regions. This 
gave 44 high-confidence 3′UTR variants. Of these, 4 vari-
ants were predicted to disrupt miRNA binding sites. These 
4 variants were found in the 3′UTR regions of 4 different 
genes: PCGF2 (c.*480G > A), RAB15 (c.*1090G > A), 
AMD1 (c.*808T > C), and FAIM (c.*46T > C) (Fig. 1b). 
Only PCGF2 has been previously implicated in ID, fol-
lowing the identification of identical missense mutations 
(NM_007144.2(PCGF2):c.194C > T; p.Pro65Leu) in two 
patients (Deciphering Developmental Disorders  Study 
2015). Each of these 3′UTR variants were found in patients 
that, at the time of testing, did not carry any known causal 
mutation (Fig. 1, Table S2). The 4 variants were predicted 
to affect the interaction of these 3′UTRs with 4 different 
miRNAs (miR-185-5p, mir-19a-3p, mir-323a-3p, and mir-
140-3p respectively).
Since the 4 miRNA binding sites were identified based on 
in silico predictions, we first determined if these predicted 
sites were indeed regulated by miRNAs by performing 
reporter assays. Constructs carrying the luciferase reporter 
gene followed by the 3′UTR sequence corresponding to the 
reference genome miRNA binding site (+) were co-trans-
fected with the relevant miRNAs to determine if the site was 
regulated (in which case we expect a reduction in reporter 
gene expression). No reliable change in expression (≥ 20% 
reduction) was observed for the binding sites in the PCGF2 
and RAB15 3′UTR regions (Fig. 2a), suggesting that these 
predictions were false positives and that they may not rep-
resent functional miRNAs sites, at least under these experi-
mental conditions. In contrast, the binding sites identified 
in the AMD1 and FAIM 3′UTR regions were substantially 
(≥ 20%) and significantly (p < 0.01) down-regulated by their 
respective miRNAs (mir-323a-3p and mir-140-3p) (Fig. 2a).
Given that the AMD1 and FAIM sites were functionally 
regulated in the ‘wild type’ reference state (+), we then 
repeated these experiments, including the identified patient 
variant (Var) to determine if the presence of the variant 
would affect this regulation. Indeed, in both cases the pres-
ence of the variant abolished repression by each of the rel-
evant miRNAs (Fig. 2b). While the reference allele (+) was 
again strongly down-regulated, introduction of the variant to 
the miRNA binding site (Var) led to reporter gene expression 
that was not significantly different from a control construct 
(−), which lacked the binding site altogether (Fig. 2b). Inter-
estingly both of the functional variants (within the AMD1 
and FAIM 3′UTRs) were found in the same individual. Upon 
repeated exome sequencing of this patient we have since 
identified a further de novo mutation in the splice site region 
of DNM1 (NM_001288739.1(DNM1):c.1197-8G > A) that 
is predicted to introduce an alternative splice site resulting 
in an out-of-frame transcript. Phenotypically this patient 
presents with IQ < 50, severe hypotonia, severe psychomo-
tor retardation and epilepsy, and congenital thoraco-lumbar 
scoliosis. These phenotypes match well with previously 
associated phenotypic features of patients with DNM1 muta-
tions, thereby making this likely to be the primary cause of 
disease.
Fig. 2  De novo variants identified in an ID cohort disrupt func-
tional miRNA binding sites. a Luciferase reporter assays were per-
formed to test the activity of the four predicted miRNA binding sites. 
Expression of the reporter was strongly (≥ ~ 20%) and significantly 
(p < 0.01) reduced in the presence of miRNA binding sites carrying 
the reference allele (+) of AMD1 and FAIM compared to an empty 
vector control (−). Significance was calculated using pairwise t test. 
Results are reported as average of three independent transfections and 
show the spread of data using the function “min to max” in GraphPad 
Prism7 (GraphPad Software, La Jolla California USA, http://www.
graph pad.com). b Introduction of the variant allele identified in the 
ID patient (“Var”) for both the AMD1 and FAIM binding sites com-
pletely abolished repression by the cognate miRNA. Significance was 
calculated using an ANOVA test, followed by post hoc Tukey calcu-
lation. Data are displayed as the percentage of repression observed 
between the control condition which consists of an empty luciferase 
reporter with no miRNA binding sites (−) and inclusion of the ref-
erence allele (+) or the variant allele (Var). Results are reported as 
average of three biological replicates (each comprising three inde-
pendent transfections) and show the spread of data using the function 
“min to max” in GraphPad Prism7. Statistical significance is indi-
cated as: *p < 0.05; **p < 0.01
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Discussion
Intellectual disability is a genetically heterogeneous 
disorder. Genetic screening of large cohorts has impli-
cated > 700 genes in the aetiology of ID (Vissers et al. 
2016; Chiurazzi and Pirozzi 2016) reflecting the complex-
ity of the underlying genetic and molecular mechanisms. 
To date, these screens have identified putatively causa-
tive mutations by focusing on large structural variants that 
affect the coding region of one or more genes, or single 
base changes in coding regions that disrupt the sequence 
and therefore function of a protein. Herein we focused 
on single nucleotide regulatory variants in patients with 
severe ID. We identified four de novo 3′UTR variants, 
across three ID patients from the cohort. Two of these var-
iants had functional consequences for miRNA-mediated 
regulation of expression and these variants were found in 
the same patient, but in two different neuronally expressed 
genes (AMD1 and FAIM). Although during our investiga-
tion this patient was diagnosed with a likely pathogenic de 
novo splice site mutation in DNM1, our results show that 
these de novo 3′UTR mutations affect gene expression, and 
as such we cannot exclude that these mutations contribute 
to the patient’s phenotype.
AMD1 is highly intolerant for loss-of-function variation 
(ExAC PLi = 0.90) and as such likely to be a haploinsuffi-
cient gene. AMD1 encodes adenosylmethionine decarbox-
ylase 1 (AdoMetDC). AdoMetDC catalyses the decarboxy-
lation of S-adenosylmethionine (AdoMet or SAM), which 
serves as a major donor of methyl groups in numerous 
reactions that involve DNA methylation (Yordanova et al. 
2018). In addition, AMD1 is essential for embryonic stem 
cell self-renewal and is translationally down-regulated 
on differentiation to neural precursor cells (Zhang et al. 
2012). FAIM encodes a protein that protects against death 
receptor-triggered apoptosis and regulates B-cell signal-
ling and differentiation. One transcript isoform is ubiqui-
tously expressed and in neurons promotes NGF-induced 
neurite outgrowth through NF-кB and ERK signalling. 
Another (longer) isoform is expressed exclusively in tis-
sues of the nervous system and is also involved in neu-
ronal differentiation (Coccia et al. 2017). It is important 
to note that, unlike deleterious coding mutations which 
usually reduce the amount of protein present, the variants 
identified herein interfere with miRNA regulation of these 
mRNAs, which would result in overexpression of these 
proteins. The consequences for overexpression of AMD1 
and FAIM proteins are currently unknown.
Mutations affecting protein coding regions can com-
pletely disrupt the function of a protein—the so-called 
loss-of-function (LOF) mutations. Conversely, variants 
found in non-coding regulatory regions are expected to 
result in more subtle consequences by affecting how much 
of the protein is present. As such, these regulatory variants 
would be expected to contribute to disease via a ‘multi-hit’ 
model in which multiple mutations would contribute to the 
phenotype. For example, multiple non-coding variants may 
need to be present in the same individual to produce a phe-
notype, or non-coding regulatory variants may be a factor 
in determining the severity of a phenotype when they are 
present alongside causative coding mutations. In this study 
we have specifically focused on regulatory variants affect-
ing the 3′UTR and miRNA-mediated regulation, however, 
these represent only the tip of the iceberg. In addition, 
future studies should consider the entire breadth of regu-
latory variants encompassing both 3′UTRs and 5′UTRs, 
alongside promoters and distal regulatory elements (e.g., 
enhancers) to determine the genetic bases of ID as this 
might uncover novel genetic mechanisms that play a role 
in ID. Looking at the whole spectrum of de novo variants, 
both in coding and non-coding regulatory regions, will be 
crucial for a full understanding of the genetic architecture 
underlying ID.
Our data show that regulatory variation in 3′UTRs can 
occur de novo in ID patients and have functional effects on 
gene expression. This new perspective shows the potential of 
non-coding variants to contribute to ID phenotypes—a cat-
egory of variation that has so far been overlooked. Although 
the prevalence of variants disrupting miRNA binding sites 
remains to be investigated in larger cohorts, we have shown 
that their biological effects at the level of gene expression 
make them important factors to consider when trying to dis-
entangle the genetic architecture of intellectual disability.
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